European urology

publication venue for

Corrigendum to "Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [¹⁷⁷Lu]Lu-PSMA-617 in the Phase 3 VISION Trial" [Eur. Urol. 86 (2024) 552-562]. 2025
Initial Experience with Single-port Robotic-assisted Kidney Transplantation and Autotransplantation. 2021
Corrigendum re "Problems with Numbers in Decision Aids for Prostate-specific Antigen Screening: A Critical Review" [Eur Urol 2021;79:330-3]. 2021
Corrigendum re: "The Impact of Prostate Size, Median Lobe, and Prior Benign Prostatic Hyperplasia Intervention on Robot-Assisted Laparoscopic Prostatectomy: Technique and Outcomes" [Eur Urol 2011;59:595-603]. 2018
Corrigendum re: "effect of a risk-stratified grade of nerve-sparing technique on early return of continence after robot-assisted laparoscopic radical prostatectomy" [Eur Urol 2013;63:438-44]. 2015
Corrigendum to "Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort" [Eur Urol 2010;57:300-9]. 2015
Corrigendum to "Focal Therapy for Prostate Cancer: Possibilities and Limitations" [Eur Urol 2010;58:57-64]. 2010
Inverted urothelial papilloma: a lesion with malignant potential. 1988
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. 2026
MLH1 Mismatch Repair Deficiency Predicts Exceptional Response to Immune Checkpoint Inhibition in Clear-cell Renal Cell Carcinoma. 2025
Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer. 2025
Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial. 2025
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease.. 88. 2025
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial.. 87. 2025
In Memory of Dr. Felix Feng.. 87. 2025
Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma. 2024
Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers.. 87. 2024
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [¹⁷⁷Lu]Lu-PSMA-617 in the Phase 3 VISION Trial.. 86. 2024
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial.. 88. 2024
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study.. 86. 2024
Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial.. 86. 2024
Safety Analyses of the Phase 3 VISION Trial of [¹⁷⁷Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.. 85. 2024
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer. 2024
Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma. 2023
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.. 85. 2023
Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression. 2023
Management of Lymph Node-positive Penile Cancer: A Systematic Review.. 85. 2023
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.. 84. 2023
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.. 83. 2023
Re: MRI-guided Focused Ultrasound Focal Therapy for Patients with Intermediate-risk Prostate Cancer: A Phase 2b, Multicentre Study.. 82. 2022
Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.. 83. 2022
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer. 2022
Re: Lymph Node Colonization Induces Tumor-immune Tolerance To Promote Distant Metastasis.. 82. 2022
Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study. 2022
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. 2022
Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling.. 82. 2022
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.. 80. 2021
Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?. 80. 2021
A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.. 80. 2021
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.. 79. 2021
Robot-assisted Radical Prostatectomy Using Single-port Perineal Approach: Technique and Single-surgeon Matched-paired Comparative Outcomes.. 79. 2020
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.. 79. 2020
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.. 78. 2020
Infertile Men Have Higher Prostate-specific Antigen Values than Fertile Individuals of Comparable Age.. 79. 2020
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.. 78. 2020
Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature.. 78. 2020
Retzius-sparing Robot-assisted Radical Prostatectomy Leads to Durable Improvement in Urinary Function and Quality of Life Versus Standard Robot-assisted Radical Prostatectomy Without Compromise on Oncologic Efficacy: Single-surgeon Series and Step-by-step Guide.. 79. 2020
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.. 78. 2020
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.. 77. 2020
Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study.. 77. 2019
Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance.. 77. 2019
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.. 77. 2019
Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights.. 76. 2019
Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect.. 76. 2019
Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.. 76. 2019
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.. 76. 2019
Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.. 76. 2018
Robotic Urologic Surgical Interventions Performed with the Single Port Dedicated Platform: First Clinical Investigation.. 75. 2018
Posterior, Anterior, and Periurethral Surgical Reconstruction of Urinary Continence Mechanisms in Robot-assisted Radical Prostatectomy: A Description and Video Compilation of Commonly Performed Surgical Techniques.. 76. 2018
Variability in Partial Nephrectomy Outcomes: Does Your Surgeon Matter?. 75. 2018
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.. 75. 2018
Are We Improving Erectile Function Recovery After Radical Prostatectomy? Analysis of Patients Treated over the Last Decade.. 75. 2018
Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group).. 74. 2018
Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes.. 74. 2018
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.. 73. 2018
Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.. 73. 2017
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.. 73. 2017
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.. 72. 2017
A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.. 72. 2017
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.. 72. 2017
Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.. 72. 2017
Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.. 72. 2017
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.. 72. 2017
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.. 72. 2017
A Systematic Approach to Discussing Active Surveillance with Patients with Low-risk Prostate Cancer.. 71. 2017
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.. 71. 2016
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.. 71. 2016
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).. 71. 2016
Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage.. 71. 2016
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.. 71. 2016
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.. 71. 2016
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.. 71. 2016
Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force.. 71. 2016
When to Perform Karyotype Analysis in Infertile Men? Validation of the European Association of Urology Guidelines with the Proposal of a New Predictive Model.. 70. 2016
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.. 70. 2016
Retraction notice to "Randomized Trial of Narrow-band Versus White-light Cystoscopy for Restaging (Second-look) Transurethral Resection of Bladder Tumors": Eur Urol 67 (2015) 605-608.. 70. 2016
Retraction notice to "Reply from Author re: Peter C. Black. Narrowing the Cystoscopy Gap. Eur Urol 2015;67:609-10: A Better Transurethral Resection-Proved or Not!": Eur Urol 67 (2015) 610-611.. 70. 2016
SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.. 71. 2016
Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition.. 70. 2016
Lethal Prostate Cancer in the PLCO Cancer Screening Trial.. 70. 2016
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.. 70. 2016
Perioperative Outcomes, Health Care Costs, and Survival After Robotic-assisted Versus Open Radical Cystectomy: A National Comparative Effectiveness Study.. 70. 2016
Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.. 71. 2016
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.. 70. 2016
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.. 70. 2016
Exploratory Decision-Tree Modeling of Data from the Randomized REACTT Trial of Tadalafil Versus Placebo to Predict Recovery of Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy.. 70. 2016
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.. 70. 2016
Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer.. 70. 2015
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.. 69. 2015
PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2.. 69. 2015
An Arterial Based Complexity (ABC) Scoring System to Assess the Morbidity Profile of Partial Nephrectomy.. 69. 2015
Unexpected Long-term Improvements in Urinary and Erectile Function in a Large Cohort of Men with Self-reported Outcomes Following Radical Prostatectomy.. 68. 2015
Genomic Characterization of Upper Tract Urothelial Carcinoma.. 68. 2015
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.. 69. 2015
A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.. 69. 2015
Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.. 69. 2015
Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy.. 68. 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.. 68. 2015
Long-term oncologic outcomes following robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.. 68. 2015
A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.. 69. 2015
Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes.. 69. 2015
Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death.. 68. 2015
Recurrence patterns after open and robot-assisted radical cystectomy for bladder cancer.. 68. 2015
Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.. 68. 2015
Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.. 68. 2015
Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial.. 67. 2014
Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer.. 68. 2014
Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.. 67. 2014
Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology.. 67. 2014
Defining a standard set of patient-centered outcomes for men with localized prostate cancer.. 67. 2014
Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial.. 67. 2014
The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.. 66. 2014
Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.. 68. 2014
Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men.. 67. 2014
Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.. 67. 2014
Randomized trial of narrow-band versus white-light cystoscopy for restaging (second-look) transurethral resection of bladder tumors.. 67. 2014
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.. 67. 2014
Technique and outcomes of robot-assisted retroperitoneoscopic partial nephrectomy: a multicenter study.. 66. 2014
Renal tumor contact surface area: a novel parameter for predicting complexity and outcomes of partial nephrectomy.. 66. 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).. 66. 2014
ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.. 66. 2014
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.. 67. 2014
Comparative effectiveness of robot-assisted versus open radical prostatectomy cancer control.. 66. 2014
Robotic partial nephrectomy with superselective versus main artery clamping: a retrospective comparison.. 66. 2014
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.. 66. 2014
Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma.. 66. 2013
Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients.. 66. 2013
Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT).. 65. 2013
Determinants of laparoscopic donor nephrectomy outcomes.. 65. 2013
Analysis of intracorporeal compared with extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.. 65. 2013
Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool.. 65. 2013
Should antibiotics be given prior to outpatient cystoscopy? A plea to urologists to practice antibiotic stewardship.. 65. 2013
Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality.. 65. 2013
Definitive pathology at radical prostatectomy is commonly favorable in men following initial active surveillance.. 66. 2013
Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival.. 65. 2013
Pathologic nodal staging scores in patients treated with radical prostatectomy: a postoperative decision tool.. 66. 2013
Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.. 65. 2013
Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.. 64. 2013
Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy.. 65. 2013
Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen.. 65. 2013
Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity.. 64. 2013
Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.. 64. 2013
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.. 63. 2012
Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial.. 64. 2012
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.. 63. 2012
Costs of radical prostatectomy for prostate cancer: a systematic review.. 65. 2012
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.. 63. 2012
Intravesical bacille Calmette-Guérin eradicates bacteriuria in antibiotic-naïve bladder cancer patients.. 63. 2012
Robotic intracorporeal orthotopic ileal neobladder: replicating open surgical principles.. 62. 2012
Effect of a risk-stratified grade of nerve-sparing technique on early return of continence after robot-assisted laparoscopic radical prostatectomy.. 63. 2012
Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy.. 63. 2012
Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.. 65. 2012
Comparison of three different tools for prediction of seminal vesicle invasion at radical prostatectomy.. 62. 2012
Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial.. 62. 2012
Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample.. 61. 2012
The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature.. 61. 2012
Technical refinement and learning curve for attenuating neurapraxia during robotic-assisted radical prostatectomy to improve sexual function.. 61. 2012
Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity.. 61. 2012
Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.. 61. 2012
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.. 62. 2012
Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current TNM classification.. 62. 2012
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.. 61. 2012
Temporal national trends of minimally invasive and retropubic radical prostatectomy outcomes from 2003 to 2007: results from the 100% Medicare sample.. 61. 2011
180-W XPS GreenLight laser therapy for benign prostate hyperplasia: early safety, efficacy, and perioperative outcome after 201 procedures.. 61. 2011
Comparison of open and minimally invasive partial nephrectomy for renal tumors 4-7 centimeters.. 61. 2011
Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.. 61. 2011
Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment.. 61. 2011
Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.. 60. 2011
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.. 60. 2011
The surgical learning curve for artificial urinary sphincter procedures compared to typical surgeon experience.. 60. 2011
Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response.. 60. 2011
Stepwise approach for nerve sparing without countertraction during robot-assisted radical prostatectomy: technique and outcomes.. 60. 2011
Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer.. 60. 2011
The impact of prostate size, median lobe, and prior benign prostatic hyperplasia intervention on robot-assisted laparoscopic prostatectomy: technique and outcomes.. 59. 2011
Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement.. 60. 2011
The prognostic significance of capsular incision into tumor during radical prostatectomy.. 59. 2010
Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center.. 59. 2010
Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension.. 59. 2010
Athermal division and selective suture ligation of the dorsal vein complex during robot-assisted laparoscopic radical prostatectomy: description of technique and outcomes.. 59. 2010
Randomized controlled trial of barbed polyglyconate versus polyglactin suture for robot-assisted laparoscopic prostatectomy anastomosis: technique and outcomes.. 58. 2010
Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy.. 58. 2010
Recovery of renal function after open and laparoscopic partial nephrectomy.. 58. 2010
GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up.. 58. 2010
Comprehensive standardized report of complications of retropubic and laparoscopic radical prostatectomy.. 57. 2009
Anatomic bladder neck preservation during robotic-assisted laparoscopic radical prostatectomy: description of technique and outcomes.. 56. 2009
Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.. 56. 2009
Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer.. 56. 2009
A comparison of postoperative complications in open versus robotic cystectomy.. 57. 2009
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.. 56. 2009
Comparative assessment of antimicrobial activities of antibiotic-treated penile prostheses.. 56. 2008
Oncologic outcome after laparoscopic radical prostatectomy: 10 years of experience.. 55. 2008
Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer.. 55. 2008
Recovery of urinary continence after radical prostatectomy: association with urethral length and urethral fibrosis measured by preoperative and postoperative endorectal magnetic resonance imaging.. 55. 2008
Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology.. 55. 2008
Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.. 55. 2008
Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience.. 55. 2008
Hydrogen sulphide is involved in testosterone vascular effect.. 56. 2008
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique.. 53. 2008
Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer.. 54. 2007
Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy.. 53. 2007
Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy.. 53. 2007
Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy.. 53. 2007
Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group.. 53. 2007
Development and validation of a premature ejaculation diagnostic tool.. 52. 2007
Risk-adjusted analysis of positive surgical margins following laparoscopic and retropubic radical prostatectomy.. 52. 2006
Preoperative and intraoperative risk factors for side-specific positive surgical margins in laparoscopic radical prostatectomy for prostate cancer.. 51. 2006
The natural history of noncastrate metastatic prostate cancer after radical prostatectomy.. 51. 2006
Anatomy and preservation of accessory pudendal arteries in laparoscopic radical prostatectomy.. 51. 2006
Impact of a multidisciplinary continuous quality improvement program on the positive surgical margin rate after laparoscopic radical prostatectomy.. 49. 2006
Positive surgical margins and accessory pudendal artery preservation during laparoscopic radical prostatectomy.. 48. 2005
A histopathologic investigation of PGE(2) pathways as predictors of proliferation and invasion in urothelial carcinomas of the bladder.. 44. 2003
Differences in gene expression in muscle-invasive bladder cancer: a comparison of Italian and American patients.. 39. 2001
Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group.. 36. 1999
Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer.. 35. 1999
Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis.. 32. 1997
Tissue polypeptide-specific antigen in renal cell carcinoma.. 30. 1996
Proscar: five-year experience.. 28. 1995
5 alpha-reductase deficiency: human and animal models.. 25 Suppl 1. 1994
5 alpha-metabolism in finasteride-treated subjects and male pseudohermaphrodites with inherited 5 alpha-reductase deficiency. A review.. 20 Suppl 1. 1991
Local BCG failures in superficial bladder cancer. A multivariate analysis of risk factors influencing survival.. 19. 1991
Patient selection for retroperitoneal lymph node dissection after chemotherapy for nonseminomatous germ cell tumors.. 19. 1991
Antigen expression in renal cell carcinoma. Correlation with histological grade, pathological stage and development of distant metastasis.. 18 Suppl 2. 1990
Chemotherapeutic management of invasive bladder carcinoma.. 14 Suppl 1. 1988
Chemotherapy and cystectomy in patients with bladder carcinoma.. 14 Suppl 1. 1988
Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen.. 78. 2020
Reply to Siebren Dijkstra and Carl J. Wijburg's Letter to the Editor re: Bernard H. Bochner, Guido Dalbagni, Karim H. Marzouk, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. Eur Urol 2018;74:465-71. Can the Pattern of Cancer Recurrence Truly be Assigned to the Surgical Modality?. 75. 2019
Re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961-7.. 75. 2018
Reply to Francesco Massari, Vincenzo Di Nunno, and Andrea Ardizzoni's Letter to the Editor re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol 2018;73:62-8.. 73. 2017
Re: Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma who have Progressed Following Treatment with Platinum-based Chemotherapy: A Single-arm, Multicenter, Phase 2 Trial.. 71. 2016
Re: Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel Risk-based Approach.. 69. 2016
Reply to Gianluca Giannarini, Alessandro Crestani, Andrea Porzionato, Veronica Macchi, and Vincenzo Ficarra's Letter to the Editor re: Massimiliano Spaliviero, Bing Ying Poon, Christoph A. Karlo, et al. An Arterial Based Complexity (ABC) Scoring System to Assess the Morbidity Profile of Partial Nephrectomy. Eur Urol 2016;69:72-9.. 69. 2015
Words of Wisdom. Re: Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists.. 67. 2015
Re: whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation.. 67. 2015
Reply to Donald L. Lamm and Nilay M. Gandhi's letter to the editor re: Behfar Ehdaie, Richard Sylvester, Harry W. Herr. Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol 2013;64:579-85.. 65. 2013
Words of wisdom. Re: antioxidants for male subfertility.. 62. 2012
Robotic transrectal ultrasonography during robot-assisted radical prostatectomy.. 62. 2012
Words of wisdom. Re: Outcome after radical cystectomy with limited or extended pelvic lymph node dissection.. 57. 2010
Prostate cancer chemotherapy. Interview by Christine McKillop.. 51. 2007
Re: Safety and Efficacy of Virtual Prostatectomy with Single-dose Radiotherapy in Patients with Intermediate-risk Prostate Cancer: Results from the PROSINT Phase 2 Randomized Clinical Trial. 2021
Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. 2020
Re: The Effect of Antioxidants on Male Factor Infertility: The Males, Antioxidants, and Infertility (MOXI) Randomized Clinical Trial. 2020
Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer. 2019
Re: Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. 2018
Re: Adjuvant Chemotherapy vs Observation for Patients with Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. 2017
Re: Radiation with or Without Antiandrogen Therapy in Recurrent Prostate Cancer. 2017
Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement. 2017
Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial. 2016
Re: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. 2016
Words of wisdom. Re: radical prostatectomy or watchful waiting in early prostate cancer. 2014
Predictors of cancer-specific mortality after disease recurrence in patients with squamous cell carcinoma of the penis. 2014
Words of wisdom. Re: Radical prostatectomy versus observation for localized prostate cancer. 2013
Reply from authors re: Manfred P. Wirth, Johannes Huber. What really matters is rarely measured: outcome of routine care and patient-reported outcomes. Eur Urol 2013;64:58-9: robot-assisted versus open radical cystectomy: beating a dead horse. 2013
Words of wisdom. Re: Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. 2012
Words of wisdom: Re: Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. 2011
Words of Wisdom. Re: use of radical cystectomy for patients with invasive bladder cancer. 2011
Words of wisdom. Re: Comparative effectiveness of minimally invasive vs open radical prostatectomy. 2010
Words of wisdom. Re: Rethinking screening for breast cancer and prostate cancer. 2010
Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. N Engl J Med 2007;356:2271-81. 2009
Words of wisdom. Re: Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML. J Urol 2008;179:1830-7; discussion 1837. 2009
Defining the Histopathological, Clinical, and Genetic Characteristics of Familial BAP1-associated Renal Cell Carcinoma. 2025
Glypican-3 as a Radiotheranostic Target for Neuroendocrine Prostate Cancer. 2025
Re: Robert Huddart, Shaista Hafeez, Clare Griffin, et al. Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomized Controlled Trial. Eur Urol 2025;87:60-70. 2025
Reply to Geoffrey H. Rosen, Nicholas H. Chakiryan, and Katie S. Murray's Letter to the Editor re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61-68. 2024
Reply to Ilias Giannakodimos' Letter to the Editor re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61-68. 2024
Reply to Peter Ka-Fung Chiu, Xiaobo Wu, Giorgio Gandaglia, European Association of Urology Young Academic Urologists Prostate Cancer Working Party. Beyond Statistical Significance: Unveiling the Advantages of Transperineal Versus Transrectal Prostate Biopsies. Eur Urol. In press. 2024
Reply to Giancarlo Marra, Marco Oderda, Paolo Gontero, and Lorenzo Richiardi's Letter to the Editor re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61-68. 2024
Re: Which Patients with Metastatic Hormone-sensitive Prostate Cancer Benefit from Docetaxel: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Trials. 2023
Reply to Fabian Falkenbach, Francesco Sanguedolce, and Lars Budäus's Letter to the Editor re: Elie Kaplan-Marans, Tenny R. Zhang, Jim C. Hu. Differing Recommendations on Prostate Biopsy Approach to Minimize Infections: An Examination of the European Association of Urology and American Urological Association Guidelines. Eur Urol. 2023;84:445-46. 2023
A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder Cancer. 2023
Re: Andrea Necchi, Laura Marandino, Daniele Raggi, et al. Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? Eur Urol 2021;79:713-6. 2021
Re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.010. 2021
Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016. 2020
Topography of Prostate Cancer Recurrence After Radiation Therapy: A Detailed Mapping Study of Salvage Radical Prostatectomy Specimens. 2017
Re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447-61. 2016
Increase in Prostate Cancer Metastases at Radical Prostatectomy in the United States. 2016
Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis. 2016
Reply to Erik Rud and Eduard Baco's Letter to the Editor re: Re: Jeffrey C. Weinreb, Jelle O. Barentsz, Peter L. Choyke, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016;69:16-40. 2016
Reply to Farshad Pourmalek, Hamidreza Abdi, and Peter C. Black's Letter to the Editor re: Daniel P. Nguyen, Bashir Al Hussein Al Awamlh, Xian Wu, et al. Recurrence Patterns After Open and Robot-assisted Radical Cystectomy for Bladder Cancer. Eur Urol 2015;68:399-405. 2015
Reply to Michael Froehner, Manfred P. Wirth's letter to the editor re: Jim C. Hu, Giorgio Gandaglia, Pierre I. Karakiewicz, et al. Comparative effectiveness of robot-assisted versus open radical prostatectomy cancer control. Eur Urol 2014;66:666-72. 2014
Reply to Michael Froehner, Rainer Koch, and Manfred P. Wirth's letter to the editor re: Karim A. Touijer, Clarisse R. Mazzola, Daniel D. Sjoberg, Peter T. Scardino, James A. Eastham. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol 2014;65:20-5. 2013
Words of wisdom: Re: Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. 2013
Re: Alberto Briganti, Thomas Wiegel, Steven Joniau, et al. early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol 2012;62:472-87: statistical concerns with Briganti radiotherapy analysis. 2013
High-resolution magnetic resonance imaging of prostatectomy specimens: a promising tool for virtual histology. 2012
Challenges of interpreting and improving radical prostatectomy outcomes: technique, technology, training, and tactical reporting. 2011
Important considerations in the clinical use of preoperative prostate cancer predictive nomograms. 2010
Re: Derya Tilki, Oliver Reich, Pierre I. Karakiewicz, et al. Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur Urol 2010;58:112-7. 2010
Why I perform robotic-assisted laparoscopic radical prostatectomy, despite more incontinence and erectile dysfunction diagnoses compared to open surgery: it's not about the robot. 2009
Re: Francesco Montorsi. A plea for integrating laparoscopy and robotic surgery in everyday urology: the rules of the game. Eur urol 2007;52:307-9. 2007
Clinical Implementation of Minimal Residual Disease Testing in Genitourinary Cancers: Bridging Promise and Practice.. 87. 2024
Aiming High: Prostate-specific Membrane Antigen Expression in Treatment-naïve Prostate Cancer.. 86. 2024
Differing Recommendations on Prostate Biopsy Approach to Minimize Infections: An Examination of the European Association of Urology and American Urological Association Guidelines.. 84. 2023
Reply to Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.022.. 84. 2023
Compound to Clinic? A Preclinical High-throughput Screening Pathway To Expedite Drug Discovery in Bladder Cancer. 2022
Leveraging Real World Genomic Data to Advance Prostate Cancer Precision Oncology.. 81. 2021
Need for Systematic Magnetic Resonance Imaging Interpretation and Reporting after Partial Prostate Gland Ablation.. 79. 2020
CDK12 Gene Alterations in Prostate Cancer: Present, but Clinically Actionable?. 78. 2020
Docetaxel for Early Prostate Cancer: What Have We Learned?. 77. 2020
Chimeric Antigen Receptor T-cell Therapy in Prostate Cancer: Reality or Folly?. 77. 2019
The Balancing Act: Assessing Treatment Burden Versus Treatment Benefit with Evolving Metastatic Hormone-sensitive Prostate Cancer Data.. 76. 2019
Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. Eur Urol 2019;76:413-5: Two Decades of World Health Organisation/International Society of Urological Pathology Bladder Cancer Grading: Time to Reflect on Accomplishments and Plan Refinement in the Molecular Era, Not Regress to Readoption of a 45-year-old Classification.. 76. 2019
Anticholinergic Burden in the Elderly Population: An Emerging Concern.. 76. 2019
Unraveling Prostate Cancer Genomics, Pathology, and Magnetic Resonance Imaging Visibility.. 76. 2019
Postchemotherapy Surgery for Advanced Urothelial Cancer: Another Tool To Improve Outcome.. 73. 2017
Anything New for Nocturia?. 72. 2017
Electronic Cigarettes: A Wolf in Sheep's Clothing.. 71. 2017
Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions.. 71. 2016
Improving Survival for Metastatic Castrate-resistant Prostate Cancer: Will Combination Therapy Help Us To Move Forward?. 70. 2016
The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer.. 70. 2016
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia.. 69. 2015
A "Chicken or Egg" Conundrum: Race, Molecular Subtype, and Tumor Location in Prostate Cancer.. 70. 2015
Reply from Authors re: Alexandre Mottrie, Giorgio Gandaglia. Do We Need a Novel Nephrometry Scoring System in Partial Nephrectomy? Eur Urol 2016;69:80-1: Nephrometry Scores for Partial Nephrectomy: The Importance of Defining a Context of Use.. 69. 2015
The Tale of Two Hypoxia-Inducible Factors in Renal Cell Carcinoma.. 69. 2015
Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use.. 69. 2015
How Should the Prevalence of Urinary Incontinence Be Determined in a Female Population?. 69. 2015
The prostatic urethral lift procedure: enough bang for the buck?. 68. 2015
Observed Advantages of the STAMPEDE Study Design.. 67. 2014
Standardization of patient-centered outcomes: less is more.. 67. 2014
Understanding long-term urinary adverse events after treatment of localized prostate cancer: a key tool in informed decision-making.. 67. 2014
Reply from Author re: Peter C. Black. Narrowing the cystoscopy gap. Eur Urol 2015;67:609-10: A better transurethral resection--proved or not!. 67. 2014
To clamp or not to clamp the main renal artery: the debate continues.. 66. 2014
Thoughts on a systematic review and meta-analysis of adjuvant chemotherapy in muscle-invasive bladder cancer.. 66. 2014
It ain't what you do, it's the way you do it: five golden rules for transforming prostate-specific antigen screening.. 66. 2014
Predicting biochemical recurrence following salvage radiotherapy: applying lessons learned from primary radiotherapy.. 66. 2014
What are the implications of the surgical learning curve?. 65. 2013
Reply from authors re: Arthur L. Burnett. Erection rehabilitation after radical prostatectomy: definite purpose, indefinite strategy. Eur Urol 2014;65:597-8: although erection rehabilitation after prostatectomy remains indefinite, the most effective treatment, the earliest recovery, and the preservation of erectile function remain a definite goal.. 65. 2013
Application of the IDEAL framework to robotic urologic surgery.. 65. 2013
Molecular characterization of prostate cancer following androgen deprivation: the devil in the details.. 66. 2013
Magnetic resonance imaging-targeted prostate biopsies: now is the time to START.. 64. 2013
Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial.. 64. 2013
Effective management of localized prostate cancer: first, do no harm.. 64. 2013
Identifying an ERG-positive subclass with clinical progression using expression profiling.. 64. 2013
Oncologic outcomes achieved by radical cystectomy.. 64. 2013
Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility.. 64. 2013
Lower urinary tract symptoms, benign prostatic hyperplasia, and prostate cancer: seek and ye shall find.. 63. 2013
5-alpha Reductase inhibitors in prostate cancer: from clinical trials to clinical practice.. 63. 2013
Artificial urinary sphincter: the workhorse for treatment of male stress urinary incontinence.. 63. 2012
Reply from Authors re: Declan G. Murphy, Anthony J. Costello. How Can the Autonomic Nervous System Contribute to Urinary Continence Following Radical Prostatectomy? A "Boson-like" Conundrum. Eur Urol 2013;63:445-7: Sparing of the Neurovascular Bundle Leads to Improved Rates of Continence.. 63. 2012
The promise and challenges of randomized controlled trials for surgical interventions.. 63. 2012
Technical advances in bladder cancer patient care: progress or promise?. 62. 2012
Is radiofrequency ablation for small kidney tumors ready for prime time?. 61. 2012
Robotic prostatectomy: the rise of the machines or judgment day.. 61. 2012
PSA is dead, long live PSA.. 61. 2011
Laparoendoscopic single-site surgery for the upper urinary tract: awaiting evidence.. 61. 2011
How do you know if you are any good? A surgeon performance feedback system for the outcomes of radical prostatectomy.. 61. 2011
The devil is in the details.. 59. 2011
Deleterious renal functional outcomes after radical nephrectomy.. 59. 2010
Marketing versus science: a fight between necessary evil and stern good over the adoption of new technology in medicine.. 58. 2010
Prediction models in urology: are they any good, and how would we know anyway?. 57. 2009
Extent of pelvic lymph node dissection during radical cystectomy: where and why!. 57. 2009
Perioperative intravesical therapy: effective treatment, unfulfilled promises.. 55. 2009
Is metastasectomy for urothelial carcinoma worthwhile?. 55. 2008
Neoadjuvant chemotherapy: a new treatment paradigm for muscle-invasive bladder cancer.. 55. 2008
Predictive modeling in prostate cancer: a conference summary.. 55. 2008
Editorial comment on: External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients.. 56. 2008
Editorial comment on: Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.. 55. 2008
Robotic-assisted prostatectomy: is there truth in advertising?. 54. 2008
Is maintenance Bacillus Calmette-Guérin really necessary?. 54. 2008
Editorial comment on: Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer.. 54. 2008
Editorial comment on: robotic-assisted laparoscopic radical cystectomy with extracorporeal urinary diversion: initial experience.. 54. 2008
Rebuttal from author re: Axel Heidenreich. Muscle-invasive urothelial carcinoma of the bladder: neoadjuvant chemotherapy enables organ preserving therapy in carefully selected patients. Eur Urol 2008;54:21-23.. 54. 2008
Editorial comment on: first analysis of the long-term results with transrectal HIFU in patients with localized prostate cancer.. 53. 2007
How many lymphadenectomies does it take to cure one patient?. 53. 2007
Detection and management of isolated lymph node recurrence in patients with PSA relapse.. 52. 2007
Should we abandon the FISH test?. 51. 2007
Neuroimmunophilin ligands protect cavernous nerves after crush injury in the rat: new experimental paradigms.. 51. 2007
Urinary continence after radical prostatectomy: "beauty is in the eye of the beholder".. 51. 2006
Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. 2018
DNA Repair in Prostate Cancer: Biology and Clinical Implications. 2016
The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. 2016
Preoperative Membranous Urethral Length Measurement and Continence Recovery Following Radical Prostatectomy: A Systematic Review and Meta-analysis. 2016
Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. 2015
A Literature Review of Renal Surgical Anatomy and Surgical Strategies for Partial Nephrectomy. 2015
Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. 2015
Renal Ischemia and Function After Partial Nephrectomy: A Collaborative Review of the Literature. 2015
A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. 2014
Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy. 2014
A review of the current status of laparoscopic and robot-assisted sacrocolpopexy for pelvic organ prolapse. 2014
Early salvage radiotherapy following radical prostatectomy. 2013
Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. 2013
The mutational landscape of prostate cancer. 2013
Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. 2013
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. 2012
Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. 2012
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. 2011
Lymph node dissection in renal cell carcinoma. 2011
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. 2011
Sequelae of treatment in long-term survivors of testis cancer. 2011
The role of laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications. 2011
A critical analysis of orthotopic bladder substitutes in adult patients with bladder cancer: is there a perfect solution? 2010
The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. 2009
Assessing the impact of ischaemia time during partial nephrectomy. 2009
Functional magnetic resonance imaging in prostate cancer. 2009
Laparoscopic radical prostatectomy: a critical analysis of surgical quality. 2006
FGFR Inhibition in Urothelial Carcinoma. 2024
Prostate-Specific Membrane Antigen-Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes. 2023
Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials. 2021
Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. 2021
Problems with Numbers in Decision Aids for Prostate-specific Antigen Screening: A Critical Review. 2020
Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. 2019
Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes. 2018
Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. 2018
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. 2018
Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8⁺ T-cells Derived from Patients with Metastatic Castrate-resistant Disease. 2017
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. 2017
Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review. 2017
Pathophysiology and Contributing Factors in Postprostatectomy Incontinence: A Review. 2016
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. 2016
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. 2016
Testosterone Therapy in Men With Prostate Cancer. 2015
Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. 2015
Patient-reported outcomes in randomised controlled trials of prostate cancer: methodological quality and impact on clinical decision making. 2013
A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. 2012
Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. 2012
Novel molecular targets for the therapy of castration-resistant prostate cancer. 2011
A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. 2011
Risk-based prostate cancer screening. 2011
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? 2011
Contemporary role of androgen deprivation therapy for prostate cancer. 2011
New therapies for castration-resistant prostate cancer: efficacy and safety. 2011
The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. 2011
Contemporary management of postprostatectomy incontinence. 2011
Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. 2011
Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy. 2011
Toxicities of targeted therapy and their management in kidney cancer. 2011
Focal therapy for prostate cancer: possibilities and limitations. 2010
A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy. 2009
Metastatic renal cell carcinoma: recent advances in the targeted therapy era. 2009
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. 2009
Complications following radical cystectomy for bladder cancer in the elderly. 2009
Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. 2008
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. 2008
Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. 2008
Current indications for chemotherapy in prostate cancer patients. 2006
The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel. 2005
Free/total prostate-specific antigen ratio--hope and controversies. 1997
Current controversies in the management of localized prostate cancer. 1995
Chemotherapy of germ cell tumors: current status and future directions. 1993
Prognostic factors for metastatic testicular germ cell tumours: the Memorial Sloan-Kettering cancer model. 1993
pT1 bladder cancer. 1991
Monoclonal antibodies to renal cancer antigens. 1990
PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer. 2024
Guidelines for reporting of statistics in European Urology. 2014
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. 2013
Guidelines on bladder cancer. 2002

VIVO Weill Cornell Medical College

European urology Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)